ijms-logo

Journal Browser

Journal Browser

Advances in Melanoma and Skin Cancers: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 29

Special Issue Editors


E-Mail
Guest Editor
Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Institute Nazionale Tumori IRCCS Fondazione “G. Pascale”, Via Mariano Semmola, 80131 Naples, Italy
Interests: oncology; translational research of skin cancers; identification of prognostic or predictive biomarkers for immunotherapy treatment; study of gene expression profile in patients with skin cancer; analysis of resistance mechanisms of immunotherapy treatment; biochemical and immunological monitoring; study of immunotherapy treatments in solid tumors; combination strategies with I-O
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Department of Oncology, San Bortolo General Hospital, ULSS 8 Berica-Vicenza, 36100 Vicenza, Italy
Interests: cancer; Immunotherapy; melanoma

E-Mail Website
Guest Editor
Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione “G. Pascale ”, Via Mariano Semmola, 80131 Naples, Italy.
Interests: skin cancers; immunotherapy; melanoma; solid tumors; immune mechanisms from Sars-CoV-2 infection in cancer patients

Special Issue Information

Dear Colleagues,

Malignant melanoma is the most aggressive skin cancer, with a high potential for relapse and metastasization. Treatment with classic chemotherapy drugs has a response rate of 10% and a short survival. The availability of immune checkpoint inhibitors (ICIs) has radically changed the prognosis not only in melanoma but also in the majority of skin cancers. Indeed, immunotherapy is currently considered the standard of care as an adjuvant therapy in high-risk resected stage III or IV melanoma, and it also demonstrates excellent results in other skin cancers. Despite these important advances, a large subgroup of patients do not respond to treatment, or relapse due to the onset of primary or acquired resistance, resulting in treatment failure in approximately 50% of patients. Therefore, it is necessary to identify specific biomarkers capable of predicting the clinical benefit of immunotherapy in melanoma and skin cancer patients.

The purpose of this Special Issue is to report the resistance mechanisms and prognostic/predictive molecular markers of immunotherapy treatment in patients with skin cancers. Original research, reviews, and short communication articles mainly focusing on the molecular basis of and advances in skin cancer immunotherapy are welcome. 

Dr. Domenico Mallardo
Dr. Debora Basile
Dr. Maria Grazia Vitale
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • immunotherapy
  • biomarkers
  • translational research
  • drug repurposing
  • clinical outcome
  • prognostic markers
  • predictive markers
  • combination immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop